सभी अध्ययन
सक्रिय लेकिन भर्ती नहींचरण3हस्तक्षेपात्मक

A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease

This research is testing a medicine called migalastat for people living with Fabry disease. It's specifically for those whose Fabry disease is linked to certain genetic changes that migalastat can help, and who also have significant kidney problems. The study will look at two groups: one with severe kidney damage who are not on dialysis, and another group who are already receiving dialysis treatment. The main goals are to understand how safe migalastat is and how the body processes it in these situations. This is an 'open-label' study, meaning both patients and doctors will know they are receiving migalastat. It's an important step to gather more information about using this treatment in people with advanced kidney disease tied to Fabry disease.

एक नजर में

स्थिति
सक्रिय लेकिन भर्ती नहीं
चरण
चरण3
प्रायोजक
Amicus Therapeutics
नामांकन लक्ष्य
14
प्रारंभ
31 अक्टूबर 2022
अनुमानित पूर्णता
31 दिसम्बर 2026

यह अध्ययन किस बारे में है?

This study is about a medicine called migalastat, used for a rare genetic condition called Fabry disease. Fabry disease can cause lots of health problems, including serious damage to the kidneys. This study is specifically for people with Fabry disease who have certain genetic changes that migalastat is known to work for, and who also have severe kidney problems.

We want to find out more about how safe migalastat is and how the body handles it in people whose kidneys are severely affected. This includes people with very advanced kidney disease who are not yet on dialysis, and also those who are already receiving dialysis treatment. We hope this study will give us valuable information to help doctors best support people with Fabry disease and kidney issues.

It's important to understand that this is an 'open-label' study. This means everyone involved – the patients and the doctors – will know that migalastat is being given. There isn't a comparison group receiving a dummy pill or a different medicine in this particular study.

मुख्य निष्कर्ष

  • This study is for adults with a specific type of Fabry disease and severe kidney problems.
  • It tests a medicine called migalastat to check its safety and how it works in people with kidney damage or on dialysis.
  • Participation involves taking migalastat and having regular check-ups.
  • You cannot join if you've had a kidney transplant or are on peritoneal dialysis.
  • This is an 'open-label' study, so everyone knows you're receiving migalastat.

कौन पात्र हो सकता है?

To join this study, you need to be an adult (18 years or older) with a diagnosis of Fabry disease. Your doctors must have noted that your specific type of Fabry disease, based on your genetic test results, is one that migalastat can help. You also need to have severe kidney problems, meaning your kidney function is quite low, as measured by a specific kidney test within the last three months and again at the start of the study.

If you have very severe kidney disease and are on dialysis, you might still be able to join. However, you would need to be on a regular dialysis schedule (2 or 3 times a week) for at least two months before starting the study. It's also important that you can receive your dialysis sessions at the study clinic or a nearby centre that the study doctor works with, and that you commit to completing all your prescribed dialysis sessions.

Unfortunately, you can't join if you've already had a kidney transplant, or if you're on a different type of dialysis called peritoneal dialysis. You also can't be taking other experimental drugs, or certain specific Fabry disease medications. If you've had certain heart problems recently, or have serious unstable heart or other medical conditions, or a history of allergic reactions to migalastat or similar drugs, you wouldn't be able to take part.

क्या यह अध्ययन आपके लिए उपयुक्त हो सकता है?

यह देखने के लिए इन त्वरित प्रश्नों का उत्तर दें कि क्या आप पात्र हो सकते हैं। यह केवल एक मार्गदर्शिका है — अंतिम निर्णय शोध टीम द्वारा लिया जाता है।.

  1. Are you 18 years or older with Fabry disease?
  2. Has your doctor confirmed your Fabry disease type can be treated with migalastat?
  3. Do you have severe kidney problems (eGFR below 30)?
  4. If on dialysis, are you on hemodialysis 2-3 times a week for at least 2 months?
  5. Have you NOT had a kidney transplant or been on peritoneal dialysis?
  6. Are you NOT taking other study drugs or certain Fabry medications currently?
अपने परिणाम देखने के लिए हर प्रश्न का उत्तर दें।.

भागीदारी में क्या शामिल है?

If you decide to take part, your first step will be a screening visit to check if you're suitable for the study. This will likely involve confirming your Fabry disease type and your kidney function. If you meet all the requirements, you'll have a main starting visit within a month. During this study, you'll be taking migalastat as prescribed.

For those on dialysis, special arrangements will be made to ensure your dialysis sessions can happen at the study clinic or an affiliated centre, and you'll need to commit to attending all your scheduled dialysis sessions. The study will involve regular check-ups and assessments to monitor your health, how the medicine is working, and to ensure your safety. The total duration of your participation will be explained to you during the consent process.

संभावित जोखिम और लाभ

Participating in this study might offer a potential benefit by giving you access to migalastat, which could help manage your Fabry disease, especially if you have significant kidney involvement. However, like all medicines, migalastat can have side effects, and some tests or procedures during the study might have their own small risks. The study team will carefully monitor your health throughout. You are free to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

स्थान (12)

  • एमोरी विश्वविद्यालय
    सत्यापित पोस्टकोड
    अटलांटा, संयुक्त राज्य अमेरिका
  • The Cleveland Clinic
    सत्यापित पोस्टकोड
    क्लीवलैंड, संयुक्त राज्य अमेरिका
  • Lysosomal and Rare Disorders Research and Treatment Center, Inc
    सत्यापित पोस्टकोड
    फेयरफैक्स, संयुक्त राज्य अमेरिका
  • Royal Melbourne Hospital
    सत्यापित पोस्टकोड
    पार्कविल, ऑस्ट्रेलिया
  • Royal Perth Hospital
    सत्यापित पोस्टकोड
    Perth, Australia
  • Osaka University Hospital
    सत्यापित पोस्टकोड
    Suita, Japan
  • Shizuoka General Hospital
    सत्यापित पोस्टकोड
    Shizuoka, Japan
  • Centro Hospitalar e Universitário de Coimbra (CHUC)
    सत्यापित पोस्टकोड
    कोइम्ब्रा, पुर्तगाल
  • Hospital Universitari(o) de Bellvitge (HUB) Feixa Llarga
    सत्यापित पोस्टकोड
    बार्सिलोना, स्पेन
  • Hospital General Universitario de Elda
    सत्यापित पोस्टकोड
    Elda, Spain
  • Hospital General Universitario Gregorio Marañon
    सत्यापित पोस्टकोड
    मैड्रिड, स्पेन
  • Salford Royal Hospital
    सत्यापित पोस्टकोड
    Salford, United Kingdom

सामान्य प्रश्न

फैब्री रोग क्या है?

Fabry disease is a rare inherited condition that can affect many parts of the body, including the kidneys, heart, and skin, because the body can't break down a certain type of fat properly.

What is migalastat?

Migalastat is a medication used to treat certain types of Fabry disease where the specific genetic change allows the drug to help the body's own enzymes work better.

Why is this study only for people with kidney problems?

This study is specifically looking at how migalastat works and its safety in people with Fabry disease who also have severe kidney damage, including those on dialysis, as there's less information about how the drug behaves in these situations.

What does 'open-label' mean?

Open-label means that everyone involved in the study – both the patient and the doctors – will know that the patient is receiving the study medication, migalastat.

क्या मुझे अध्ययन में शामिल होने के लिए भुगतान करना होगा?

No, you will not have to pay for the study medication or any study-related tests and appointments. Travel costs may also be reimbursed.

और अधिक जानने के लिए कैसे पता करें

किसी अध्ययन में भाग लेने का निर्णय लेने से पहले हमेशा अपने जीपी या विशेषज्ञ से बात करें।.

चर्चा

समुदाय चर्चा

हमारे फोरम द्वारा संचालित community.patient.info. कृपया सम्मानजनक रहें — यह चिकित्सा सलाह नहीं है।.